Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Dec 2, 2024 • 18min
From Approval to Practice: Managing Side Effects of Antibody Drug Conjugates (ADC) in Cancer
Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD).
Episode Highlights:
• Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice.
• Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care.
• Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management.
This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs.
Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Nov 28, 2024 • 23min
The use of Immunotherapy in unresectable Hepatocellular Carcinoma (HCC)
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data.
Topics also include:
• Efficacy and safety of IO and IO combinations in HCC
• How to select between the two 1st-line IO-based treatment options based on clinical factors
• Future treatment in unresectable HCC
Clinical Takeaways
• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary
• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Nov 25, 2024 • 23min
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study.
Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations.
Key topics discussed include:
• Overview of the INAVO120 study and its significance
• The unique patient population targeted in the study
• Key findings, including the impressive improvement in progression-free survival (PFS)
• Side effects and management strategies for patients
• The importance of genetic testing in treatment decisions
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment.
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Nov 21, 2024 • 22min
How to Approach and Treat Pancreatic Cancer
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rohit and Rahul Gosain are joined by Dr. Eileen O'Reilly, a leading medical oncologist and section head of hepatobiliary and pancreatic cancer at Memorial Sloan Kettering Cancer Center. Together, they delve into the complex treatment landscape of pancreatic cancer.
Episode Highlights:
The initial workup for newly diagnosed pancreatic cancer patients, including the importance of imaging and genetic testing.
Treatment paradigms for early-stage, borderline resectable, and metastatic pancreatic cancer.
The role of multi-agent chemotherapy, including modified FOLFIRINOX and gemcitabine-nab-paclitaxel.
Insights into managing patients with high bilirubin levels and the considerations for dose adjustments.
The emerging role of targeted therapies and the significance of comprehensive genetic testing in treatment decisions.
Join us as we explore the latest standards of care, the importance of a multidisciplinary approach, and the potential of new therapies in improving outcomes for patients with pancreatic cancer.
Don't forget to like, subscribe, and check out our other episodes for more insights on oncology topics, conference highlights, and recent treatment approvals!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Nov 18, 2024 • 18min
Understanding the Impact of Nutrition & Exercise on Cancer Outcomes
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Neil Iyengar, a medical oncologist from Memorial Sloan Kettering Cancer Center, to discuss the critical role of nutrition and exercise in cancer care and recurrence prevention.
They tackle common questions from cancer survivors about lifestyle modifications that can help reduce the risk of cancer recurrence. With the current hype around various diets, the discussion delves into the evidence surrounding dietary patterns, exercise, and their impact on overall health and cancer outcomes.
Key topics included:
• The mixed evidence regarding diet and exercise in preventing cancer recurrence.
• The limitations of BMI as a measure of health and its implications in cancer studies.
• Insights from recent breast cancer trials on diet and survival rates.
• The importance of social determinants of health in dietary recommendations.
• Practical dietary guidelines and the significance of high-fiber, fruit-and-vegetable-rich diets.
Dr. Iyengar emphasized the need for ongoing research to provide more specific dietary recommendations for different cancer types and highlights resources available for patients and healthcare providers.
Join us for an informative discussion that aimed to empower cancer patients and healthcare professionals with knowledge about lifestyle interventions that can enhance quality of life and potentially improve cancer outcomes.
Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Nov 14, 2024 • 21min
How to Diagnose, Treat, and Follow Neuroendocrine Tumors (NETs)
Dr. Pamela Kunz, a leading medical oncologist from the Yale Cancer Center, dives into the complex world of neuroendocrine tumors (NETs). She highlights the significance of the KI-67 marker in tumor classification and the role of advanced imaging like Gallium PET-CT. The discussion covers treatment strategies for both localized and metastatic cases, explaining the use of somatostatin analogs and newer therapies like lutetium dotatate. Insights into next-generation sequencing and the evolving treatment landscape make this a must-listen for oncology enthusiasts.
Nov 8, 2024 • 26min
Palliative Care Management in Cancer
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by esteemed palliative care experts Dr. Janet Abrahm from Dana-Farber Cancer Institute and Dr. Ishwaria Subbiah from Sarah Cannon Research Institute. Together, they delve into the critical topic of palliative care, exploring its evolution from a focus on end-of-life care to an integral part of cancer treatment that enhances both longevity and quality of life.
Key discussion points include:
• The definition and importance of palliative care as an "extra layer of support" for patients, families, and oncologists.
• The stigma surrounding palliative care and the potential benefits of rebranding it as supportive care.
• The significant impact of palliative care on symptom management and overall patient outcomes.
• Innovative approaches to integrating palliative care into oncology practices, including the use of technology and multidisciplinary teams.
• Effective communication strategies for discussing palliative care and advanced care planning with patients and their families.
Join us for this enlightening conversation that aims to demystify palliative care and highlight its essential role in cancer care. Don't forget to like, subscribe, and share your thoughts in the comments!
#OncologyBrothers #PalliativeCare #CancerCare #SupportiveCare #QualityOfLife #SymptomManagement #AdvancedCarePlanning
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Oct 31, 2024 • 20min
How to Approach to Ovarian Cancer from Community Oncology Perspective
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain welcome Dr. Martina Murphy, an Associate Professor of Medicine and Senior Associate Dean of Graduate Medical Education at the University of Florida, to discuss the current landscape of ovarian cancer.
Join us as we dive into the critical aspects of diagnosing and managing ovarian cancer, including:
• The importance of surgical staging and primary debulking surgery
• The role of genetic testing, including BRCA and NGS, in treatment planning
• Adjuvant therapy options, focusing on platinum-based chemotherapy and the use of Bevacizumab
• Insights into PARP inhibitors and their application in BRCA-positive and wild-type patients
• Navigating treatment options for relapsed and refractory ovarian cancer, including the use of antibody-drug conjugates like Mirvetuximab and Trastuzumab Deruxtecan (TDXd).
Dr. Murphy shares her expertise on the latest advancements in ovarian cancer treatment, the significance of genetic testing, and the management of side effects associated with various therapies.
Tune in for a comprehensive overview of the standard of care for ovarian cancer and the evolving treatment landscape. Don't forget to check out our other episodes for more discussions on practice-changing data and current treatment options in oncology!
Subscribe to the Oncology Brothers podcast for more insights and updates in the field of oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
6 snips
Oct 24, 2024 • 25min
How to Approach to Endometrial Cancer from Community Oncology Perspective
Dr. Shannon Westin, a leading Professor at MD Anderson Cancer Center, shares her expertise on endometrial cancer. She delves into the various histologies and the importance of molecular classification in treatment decisions. Listeners will learn about current strategies for early-stage and advanced cancers, including the role of surgery and the promising combination of chemotherapy and immunotherapy. The discussion also highlights the significance of Next-Generation Sequencing in personalizing treatment for patients, offering vital insights for healthcare professionals.
Oct 22, 2024 • 18min
DeLLphi-301 - FDA Approval of Tarlatamab in Patients w/ Prev Treated Small Cell Lung Cancer (SCLC)
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:
• The study's primary endpoint of objective response rate and its implications for patient care.
• The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells.
• The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
• Strategies for community oncologists to effectively manage patients receiving this new treatment.
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
